New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.
about
Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulationChallenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewMonitoring anticoagulant therapy with new oral agentsSafety of new oral anticoagulant drugs: a perspectiveRisk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational StudiesEfficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden.Treatment options for venous thromboembolism: lessons learnt from clinical trials.Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty.Current state of anticoagulants to treat deep venous thrombosis.Oral anticoagulants in the management of venous thromboembolism.Novel oral anticoagulants in cardiovascular disease.Extraosseous calcification in end-stage renal disease: from visceral organs to vasculature.New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation.Real-world stroke prevention strategies in nonvalvular atrial fibrillation in patients with renal impairment.Oral anticoagulants and risk of nephropathy.New Oral Anticoagulants: How Do We Use Them Wisely?New oral anticoagulants - a guide for ENT surgeons.Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?Atrial Fibrillation and Renal Disease.Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study.Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents.Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease.Use Patterns and Unlabeled Uses of Target-Specific Oral Anticoagulants: A Single-Center Experience.
P2860
Q26749141-1772295A-B76E-4733-AF2D-7543A0197A5BQ26765949-1D8D1127-F1F0-46FD-AC23-E075101569BDQ26771728-84FEA584-90AC-46ED-A72C-C6537295F346Q27016072-67FF1292-181D-46C6-898A-63216DC12883Q28078747-6C962359-9FAB-4422-B030-D7EA480E13B0Q34694471-5AE778AB-F833-4F8F-B5B9-ED7A920E1C09Q34694544-EEE829D6-D9F7-4555-8385-31914C2E94EFQ34938763-63412233-EF5A-4416-9F5F-1B7AE07EF2F3Q37638073-F6BBA966-2B6A-4051-A2AD-44F9DF7B0E42Q38108205-4C588A7E-BFC4-47A1-A3D2-1AB52A6C2004Q38137852-07CAF464-99D3-44D2-979D-2CF0592F6251Q38179484-2A01ACB4-0875-47F2-A1B1-594395CEC26BQ38203298-B5BB11E6-6E75-4009-ABA0-9459CC5716E2Q38262325-F4404476-A9E9-47B2-9B54-1B29EA82F5DFQ38378124-AE7CB88D-E3CD-4707-ACC2-41EB82882193Q38443104-508DF1BB-8018-4114-B163-9E717D9CDC23Q38560059-902862B0-5BB1-42BB-AE8C-469521034809Q38718202-A849C4D5-CE2C-4CF4-8FD0-9078EC10B4F2Q38728028-E469B42A-FCF7-4112-A1D7-4957B376BE86Q38790393-377CD56B-5C63-436E-9739-E29787D86764Q43837028-3F727B22-E60B-48D3-9E0A-5375A04C2765Q46915951-FCFB8763-C1CA-4F69-8B8E-CBEE6A6C0D0EQ48152210-77DDE9E5-9944-4A81-9770-D1141EABAC61Q50002162-3A1C7C86-3147-4927-B12A-AAE1B6A007BAQ53089586-9E677DA3-D2D3-4ED3-8A2D-DC07CCB92DC3Q55220400-FB070E9B-C1D8-496D-8C0D-34D6EFD339A7
P2860
New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New oral anticoagulants: a rev ...... with impaired renal function.
@en
type
label
New oral anticoagulants: a rev ...... with impaired renal function.
@en
prefLabel
New oral anticoagulants: a rev ...... with impaired renal function.
@en
P2093
P2860
P1433
P1476
New oral anticoagulants: a rev ...... with impaired renal function.
@en
P2093
Birgitte Klindt Poulsen
Erik Lerkevang Grove
Steen Elkjaer Husted
P2860
P304
P356
10.2165/11635730-000000000-00000
P577
2012-09-01T00:00:00Z
P5875
P6179
1010854026